阿尔茨海默病发展的一个模型
Zhenyu Huang1,2, Xuechen Mu2,3, Qiufen Chen2
1College of Computer Science and Technology, Jilin University, Changchun 130012, China.
Genomics, proteomics & bioinformatics
|September 23, 2025
概括
阿尔茨海默病 (AD) 涉及细胞内性和细胞外酸性. 这项研究模拟了炎症,新陈代谢变化和神经递质失衡如何推动阿尔茨海默病的进展,揭示了疾病发展的新型系统层面观点.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 的特征是细胞内性和细胞外酸性.
- 在阿尔茨海默病中这些pH不平衡的根本原因和后果仍然不完全理解.
研究的目的:
- 从AD组织中计算分析和建模转录组数据.
- 阐明在阿尔茨海默氏症中pH调节失调的原因和后果.
主要方法:
- 来自阿尔茨海默氏病组织的转录基因数据的计算分析.
- 系统级建模以了解细胞pH调节及其破坏.
主要成果:
- 慢性炎症和改变的铁/铜代谢会导致持续的线粒体化.
- 细胞激活产生酸的途径,特别是谷氨酸水解,导致细胞外谷氨酸释放和神经元过激动.
- 损伤的天体细胞二碳酸盐释放会加剧细胞外化,导致神经元死亡.
- 阿尔茨海默病的特征,如Aβ聚合物和Tau纠结,最初有助于pH平衡,但后来有助于疾病进展.
结论:
- 一个新的模型解释了阿尔茨海默病的发展,通过一连串的pH失调.
- 突出了炎症,新陈代谢,神经传递和AD病理之间的相互作用.
- 表明pH不平衡是阿尔茨海默氏症病原发生的中心机制.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.7K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.2K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825